Consistency-Guided Temperature Scaling Using Style and Content Information for Out-of-Domain Calibration

Research interests in the robustness of deep neural networks against domain shifts have been rapidly increasing in recent years. Most existing works, however, focus on improving the accuracy of the model, not the calibration performance which is another important requirement for trustworthy AI systems. Temperature scaling (TS), an accuracy-preserving post-hoc calibration method, has been proven to be effective in in-domain settings, but not in out-of-domain (OOD) due to the difficulty in obtaining a validation set for the unseen domain beforehand. In this paper, we propose consistency-guided temperature scaling (CTS), a new temperature scaling strategy that can significantly enhance the OOD calibration performance by providing mutual supervision among data samples in the source domains. Motivated by our observation that over-confidence stemming from inconsistent sample predictions is the main obstacle to OOD calibration, we propose to guide the scaling process by taking consistencies into account in terms of two different aspects -- style and content -- which are the key components that can well-represent data samples in multi-domain settings. Experimental results demonstrate that our proposed strategy outperforms existing works, achieving superior OOD calibration performance on various datasets. This can be accomplished by employing only the source domains without compromising accuracy, making our scheme directly applicable to various trustworthy AI systems.Comment: Accepted at AAAI-24 (The 38th AAAI Conference on Artificial Intelligence, February 2024

The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke

Aim/Background: This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. Methods: We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. Results: By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort

Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea

Viral respiratory diseases (VRDs) cause lung inflammation and inflammatory cytokine production. We study whether dapsone is responsible for its observed preventive treatment effects of the sustained viral RNA interferon response. Around 2008 and 2012, Korea’s Dementia Management Act stipulated drastic changes in the administration of dementia medication by medical staff. Participants were randomized and we compared leprosy patients with VRDs after prescribing dapsone as a standard treatment from 2005 to 2019. Significance was evaluated based on the dapsone-prescribed (+) subgroup and the dapsone-unprescribed (−) subgroup of the VRD diagnosed (+) and VRD undiagnosed (−) subgroup. We analyzed VRD (+)/(− with dapsone (+)/(−) group and used a T-test, and designed the equation of acetylation with dapsone and acetylcholine (AA) equation. The 6394 VRD participants who received the dapsone intervention compared to the 3255 VRD participants in the control group demonstrated at T2 VRD (+) dapsone (−) (mean (M) = 224.80, SD = 97.50): T3 VRD (−) dapsone (+) (M = 110.87, SD = 103.80), proving that VRD is low when dapsone is taken and high when it is not taken. The t value is 3.10, and the p value is 0.004395 (significant at p < 0.05). After an increase in VRDs peaked in 2009, bronchitis, COPD, and pneumonia surged in 2013. The AA equation was strongly negatively correlated with the prevalence of bronchitis and chronic obstructive pulmonary disease (COPD): with bronchitis, r(15) = −0.823189, p = 0.005519, and with COPD, r(15) = −0.8161, p = 0.000207 (significant at p < 0.05). Dapsone treated both bronchitis and COPD. This study provides theoretical clinical data to limit acetylcholine excess during the VRD pandemic for bronchitis, COPD, and pneumonia